What's Happening?
Apreo Health, a medical device company, presented new clinical data at the European Respiratory Society Congress 2025 in Amsterdam, showcasing the efficacy of its BREATHE Airway Scaffold. This device is designed to treat severe emphysema by releasing air from hyperinflated lungs. The data, derived from the BREATHE 1&2 First In Human studies, indicate significant improvements in lung function and quality of life for patients, including those typically excluded from other treatments. The scaffold demonstrated a 92.4% technical success rate and no post-procedural pneumothorax, a common complication in lung volume reduction procedures. The studies highlighted the scaffold's ability to maintain airway patency and reduce hyperinflation, offering a minimally invasive alternative to traditional surgical methods.
Why It's Important?
The introduction of the BREATHE Airway Scaffold represents a significant advancement in the treatment of emphysema, a condition affecting millions in the U.S. This device offers a less invasive option compared to existing surgical treatments, potentially expanding access to care for patients who are not candidates for surgery. The scaffold's ability to improve lung function and quality of life without the risks associated with more invasive procedures could transform the treatment landscape for emphysema. This development is particularly crucial as emphysema remains a leading cause of disability and mortality, with limited interventional options available.
What's Next?
Following the promising results from the BREATHE 1&2 trials, Apreo Health is likely to pursue further clinical studies to validate these findings and seek broader regulatory approvals. The company may also explore partnerships with healthcare providers to integrate this technology into standard care practices for emphysema. As the device gains traction, it could prompt a reevaluation of treatment protocols for emphysema, potentially influencing insurance coverage and reimbursement policies.
